228 related articles for article (PubMed ID: 21506251)
1. Immunosuppression and hepatocellular carcinoma.
Schlitt HJ; Mornex F; Shaked A; Trotter JF
Liver Transpl; 2011 Oct; 17 Suppl 2():S159-61. PubMed ID: 21506251
[No Abstract] [Full Text] [Related]
2. Treatment of recurrent hepatocellular carcinoma after liver transplantation.
Davis E; Wiesner R; Valdecasas J; Kita Y; Rossi M; Schwartz M
Liver Transpl; 2011 Oct; 17 Suppl 2():S162-6. PubMed ID: 21688382
[No Abstract] [Full Text] [Related]
3. Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation?
Grant D; Fisher RA; Abecassis M; McCaughan G; Wright L; Fan ST
Liver Transpl; 2011 Oct; 17 Suppl 2():S133-8. PubMed ID: 21634006
[No Abstract] [Full Text] [Related]
4. Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation.
Kneteman N; Livraghi T; Madoff D; de Santibañez E; Kew M
Liver Transpl; 2011 Oct; 17 Suppl 2():S117-27. PubMed ID: 21584926
[No Abstract] [Full Text] [Related]
5. Which matters most: number of tumors, size of the largest tumor, or total tumor volume?
Germani G; Gurusamy K; Garcovich M; Toso C; Fede G; Hemming A; Suh KS; Weber A; Burroughs AK
Liver Transpl; 2011 Oct; 17 Suppl 2():S58-66. PubMed ID: 21584928
[No Abstract] [Full Text] [Related]
6. Should we perform deceased donor liver transplantation after living donor liver transplantation has failed?
Greig PD; Geier A; D'Alessandro AM; Campbell M; Wright L
Liver Transpl; 2011 Oct; 17 Suppl 2():S139-46. PubMed ID: 21563294
[No Abstract] [Full Text] [Related]
7. What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma?
Duvoux C; Kiuchi T; Pestalozzi B; Busuttil R; Miksad R
Liver Transpl; 2011 Oct; 17 Suppl 2(Suppl 2):S147-58. PubMed ID: 21714065
[No Abstract] [Full Text] [Related]
8. Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma?
Yao FY; Breitenstein S; Broelsch CE; Dufour JF; Sherman M
Liver Transpl; 2011 Oct; 17 Suppl 2():S109-16. PubMed ID: 21584927
[No Abstract] [Full Text] [Related]
9. Recurrence of hepatocellular carcinoma after liver transplantation: is immunosuppression a factor?
Schwartz M; Konstadoulakis M; Roayaie S
Liver Transpl; 2005 May; 11(5):494-6. PubMed ID: 15838915
[No Abstract] [Full Text] [Related]
10. Should we use living donor grafts for patients with hepatocellular carcinoma? Ethical considerations.
Pomfret EA; Lodge JP; Villamil FG; Siegler M
Liver Transpl; 2011 Oct; 17 Suppl 2():S128-32. PubMed ID: 21656657
[No Abstract] [Full Text] [Related]
11. What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation?
Olthoff KM; Forner A; Hübscher S; Fung J
Liver Transpl; 2011 Oct; 17 Suppl 2():S26-33. PubMed ID: 21656653
[No Abstract] [Full Text] [Related]
12. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
[TBL] [Abstract][Full Text] [Related]
13. [Liver transplantation for hepatocellular carcinoma].
Tanaka A; Tanaka K; Kaihara S; Ueda M; Uemoto S; Kiuchi T; Egawa H
Nihon Rinsho; 2001 Oct; 59 Suppl 6():705-16. PubMed ID: 11762042
[No Abstract] [Full Text] [Related]
14. Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation: a gap between basic science and clinical evidence.
Schnitzbauer AA; Schlitt HJ; Geissler EK
Transplantation; 2011 Jun; 91(11):1173-6. PubMed ID: 21427632
[TBL] [Abstract][Full Text] [Related]
15. Living donor liver transplantation in patients who have received pretransplant treatment for hepatocellular carcinoma.
Yoshizumi T; Shirabe K; Soejima Y; Taketomi A; Ikegami T; Uchiyama H; Harada N; Ijichi H; Maehara Y
Transplantation; 2011 Apr; 91(8):e61-2. PubMed ID: 21475066
[No Abstract] [Full Text] [Related]
16. 2010 International Consensus Conference on Liver Transplantation for Hepatocellular Carcinoma: texts of experts.
Lesurtel M; Clavien PA
Liver Transpl; 2011 Oct; 17 Suppl 2():S1-5. PubMed ID: 21656651
[No Abstract] [Full Text] [Related]
17. Immunosuppression does not enhance tumor growth after orthotopic liver transplantation for hepatoma.
Steininger R; Herbst F; Függer R; Mühlbacher F; Fritsch A
Transplant Proc; 1992 Dec; 24(6):2690-2. PubMed ID: 1334597
[No Abstract] [Full Text] [Related]
18. Recurrent hepatocellular carcinoma after living donor liver transplantation: a preventable problem or an acceptable risk?
Sonnenday CJ
Ann Surg Oncol; 2010 Sep; 17(9):2262-3. PubMed ID: 20431956
[No Abstract] [Full Text] [Related]
19. Analysis of risk factors for recurrence of hepatocellular carcinoma after orthotopic liver transplantation.
Lohmann R; Bechstein WO; Langrehr JM; Knoop M; Lobeck H; Keck H; Lemmems HP; Blumhardt G; Neuhaus P
Transplant Proc; 1995 Feb; 27(1):1245-6. PubMed ID: 7533376
[No Abstract] [Full Text] [Related]
20. Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival.
Fahrner R; Dondorf F; Ardelt M; Dittmar Y; Settmacher U; Rauchfuß F
World J Gastroenterol; 2015 Nov; 21(42):12071-82. PubMed ID: 26576092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
